



11/11 GP1615

CERTIFICATE OF MAILING

Hereby certify that the below listed items are being deposited with the U.S. Postal Service as first class mail in an envelope addressed to:

Mail Stop
Commissioner for Patents
P.O. Box 1450
Alexandria, Virginia 22313-1450

on 9/11/2006.

Laurie Delesandro
Laurie Delesandro

In Re Application of:

Jo, Hanjoong

Group Art Unit:

Serial No.: **10/541,953**

Examiner:

Filed: **July 12, 2005**

Docket No. **820701-1215**

For: Anti-Inflammatory Agents and Methods of Their Use

The following is a list of documents enclosed:

Return Postcard
Information Disclosure Statement

Further, the Commissioner is authorized to charge Deposit Account No. 20-0778 for any additional fees required. The Commissioner is requested to credit any excess fee paid to Deposit Account No. 20-0778.

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In Re Application of:

Jo, Hanjoong

Serial No.: 10/541,953

Filed: July 12, 2005



Confirmation No.: 8928

Group Art Unit:

Examiner:

Docket No.: 820701-1215

For: Anti-Inflammatory Agents and Methods of Their Use

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
 P.O. Box 1450
 Alexandria, Virginia 22313-1450

Sir:

This information disclosure statement is filed in accordance with 37 C.F.R. §§ 1.56, 1.97, and 1.98, and specifically:

under 37 CFR 1.97(b), or
 (within Three months of filing national application, or date of entry of international application; or before
 mailing date of first office action on the merits; whichever occurs last)

under 37 CFR 1.97(c) together with either a:
 Statement Under 37 C.F.R. 1.97(e), or
 a \$180.00 fee under 37 CFR 1.17(p), or
 (After the CFR 1.97(b) time period, but before the final office action or notice of allowance, whichever
 occurs first)

under 37 CFR 1.97(d) together with a:
 Statement under 37 CFR 1.97(e), and
 a \$180.00 petition fee set forth in 37 CFR 1.17(p).
 (Filed after final office action or notice of allowance, whichever occurs first, but before payment of the
 issue fee)

Enclosed is a check in the amount of \$. Please charge \$ to deposit account . At any time during the pendency of this application, please charge any fees required to Deposit Account 20-0778 pursuant to 37 CFR 1.25. The Commissioner is hereby requested to credit any overpayment to Deposit Account No. 20-0778.

Applicant(s) submit herewith *Form PTO/SB/08A - Information Disclosure Statement by Applicant* together with copies of patents, publications or other information of which applicant(s) are aware, which applicant(s) believe(s) may or may not be material to the examination of this application and for which there may be a duty to disclose in accordance with 37 CFR 1.56. As required by 37 C.F.R. §1.98(a), a legible copy of each document is provided.

A concise explanation of the relevance of foreign language patents, foreign language publications and other foreign language information listed on PTO Form 1449, as presently understood by the individual(s) designated in 37 CFR 1.56(c) most knowledgeable about the content is given on the attached sheet, or where a foreign language patent is cited in a search report or other action by a foreign patent office in a counterpart foreign application, an English language version of the search report or action which indicates the degree of relevance found by the foreign office is listed on the form PTO/SB/08A and is enclosed herewith.

The following rights are reserved by the Applicant(s): the right to establish the patentability of the claimed invention over any of the listed documents should they be applied as reference, and/or the right to prove that some of these documents may not be prior art, and/or the right to prove that some of these documents may not be enabling for the teachings they purport

to offer.

This statement should not be construed as a representation that an exhaustive search has been made, or that information more material to the examination of the present application does not exist. Any statements or identifications regarding the relevance of any portion(s) of cited references should not be construed as a representation that the most relevant portion(s) have been identified, and the absence of such statements or identifications should not be construed as representations that there are no relevant portion(s). The Examiner is specifically requested not to rely solely on the materials submitted herewith. The Examiner is requested to conduct an independent and thorough review of the documents, and to form independent opinions as to their significance.


Applicant also submits a search report issued by the U.S. Patent and Trademark Office as the International Search Authority in connection with PCT/US04/00759.

It is requested that the information disclosed herein be made of record in this application and that the Examiner initial and return a copy of the enclosed PTO/SB/08A to indicate the documents have been considered.

Respectfully Submitted,

THOMAS, KAYDEN, HORSTEMEYER
& RISLEY, LLP.

By:


Todd Deveau, Reg. No. 29,526

100 Galleria Parkway, Suite 1750
Atlanta, Georgia 30339-5948
770-933-9500

Form PTO-1449



INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

Attorney Docket No.
820701-1215Serial No.
10/541,953Applicant
Jo, HanjoongFiling Date
07/12/2005Group
Unknown

U.S. PATENT DOCUMENTS

Examiner Initials	Item	Document Number	Date	Name	Class	Subclass	Filing Date If Appropriate
	A						
	B						
	C						
	D						
	E						
	F						
	G						
	H						
	I						
	I						
	K						

FOREIGN PATENT DOCUMENTS

		Document Number	Date	Country	Class	Subclass	Translation	
							Yes	No
/ECK/	L	WO 00/56879	09/28/00	WIPO				
/ECK/	M	WO 98/49296	11/05/98	WIPO				
	N							
	O							

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc.)

/ECK/	P	Schmitt, et al., Bone Morphogenic Proteins: An Update on Basic Biology and Clinical Relevance. J Orthopaedic Res. 1999; 17:269-278, see esp. p. 275, left column, 2nd paragraph
/ECK/	Q	Moyad MA, Semin Urol Oncol. An Introduction to Aspirin, NSAIDSS, and COX02 Inhibitors for the Primary Prevention of Cardiovascular Events and Cancer and Their Potential Preventive Role in Bladder Carcinogenesis: Part I. 2001; 19: 294-305, entire document
/ECK/	R	Renu et al. Curr Opin Lipidol. Pathology of in-stent restenosis. 1999; 10: 499-506.

* EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to the applicant.

EXAMINER'S SIGNATURE: /Elizabeth C. Kemmerer/

DATE CONSIDERED: 05/22/2008